Effects of immune checkpoint inhibitor therapy resumption in patients with malignant tumors after moderate-to-severe immune-related adverse events.

<h4>Background and aims</h4>Immune checkpoint inhibitors (ICIs) are used to treat several cancers, but they sometimes induce immune-related adverse events (irAEs). Patients with irAEs often have improved antitumor responses, but discontinuation of ICIs after irAEs is considered necessary. Resuming t...

Fuld beskrivelse

Bibliografiske detaljer

Principais autores:	Machiko Kawahira, Shuji Kanmura, Keiko Mizuno, Kentaro Machida, Takao Ohtsuka, Masami Sato, Hideki Enokida, Masaru Yamashita, Takuro Kanekura, Shiho Arima, Norifumi Nakamura, Tsuyoshi Sugiura, Koji Yoshimoto, Hiroaki Kobayashi, Kenji Ishitsuka, Shinsuke Suzuki, Shinichi Ueno, Akio Ido
Format:	Artigo
Sprog:	Inglês
Udgivet:	Public Library of Science (PLoS) 2022-01-01
Serier:	PLoS ONE
Online adgang:	https://doi.org/10.1371/journal.pone.0267572
Tags:	Tilføj Tag Ingen Tags, Vær først til at tagge denne postø!